Advertisement

C-Reactive Protein Level Predicts Survival Outcomes in Rectal Cancer Patients Undergoing Total Mesorectal Excision After Preoperative Chemoradiation Therapy

  • Woo Ram Kim
  • Yoon Dae Han
  • Byung Soh Min
Colorectal Cancer

Abstract

Background

Systemic inflammatory response, as measured by C-reactive protein (CRP), is associated with prognosis in various types of human malignancies. However, to the best of our knowledge, the clinical significance of CRP in patients with locally advanced rectal cancer that undergo preoperative chemoradiation has not been investigated in detail. This retrospective study validates CRP as a potential predictive marker for survival outcomes in rectal cancer patients.

Methods

In this study, we enrolled 125 patients that received total mesorectal excision after preoperative chemoradiation for rectal cancer between January 2003 and December 2010. We investigated the association between preoperative CRP and clinicopathological characteristics and assessed the prognostic value of CRP.

Results

The median follow-up was 41 months. Elevated CRP showed significant correlation with high histological grade (P = 0.009) and cancer recurrence (P = 0.027). The 5-year disease-free survival and cancer-specific survival were significantly lower in the elevated CRP group (P = 0.001). Moreover, CRP was the strongest predictive factor for cancer-specific survival in multivariate analysis (P = 0.001). In the subgroup analysis, elevated CRP was a significant prognostic factor in patients with node-positive disease (P = 0.025) and was associated with poorer tumor regression (TRG4–5; P = 0.011).

Conclusions

The results of our study suggest that preoperative CRP level shows prognostic significance in rectal cancer patients that have undergone chemoradiation. Therefore, preoperative CRP may help clinicians to identify patients that need additional therapy to reduce systemic failure.

Notes

Acknowledgement

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and funded by the Korea Government (Ministry of Science, ICT and Future Planning, MSIT; Grant No. 2017R1C1B5076797).

Disclosure

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.CrossRefGoogle Scholar
  2. 2.
    Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4(8):641–8.CrossRefGoogle Scholar
  3. 3.
    Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006;94(11):1568–71.CrossRefGoogle Scholar
  4. 4.
    Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007;61(9):824–33.CrossRefGoogle Scholar
  5. 5.
    Kim DK, Oh SY, Kwon HC, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009;9:155.CrossRefGoogle Scholar
  6. 6.
    Leitch EF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97(9):1266–70.CrossRefGoogle Scholar
  7. 7.
    Nagaoka S, Yoshida T, Akiyoshi J, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 2007;27(8):1091–7.CrossRefGoogle Scholar
  8. 8.
    Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011;103(14):1112–22.CrossRefGoogle Scholar
  9. 9.
    Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141–212.CrossRefGoogle Scholar
  10. 10.
    Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998;176(4):335–8.CrossRefGoogle Scholar
  11. 11.
    Canna K, McArdle PA, McMillan DC, et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005;92(4):651–4.CrossRefGoogle Scholar
  12. 12.
    Dreanic J, Maillet M, Dhooge M, et al. Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies. Med Oncol. 2013;30(3):656.CrossRefGoogle Scholar
  13. 13.
    Fukuchi M, Kuwabara K, Tsuji Y, et al. C-reactive protein is a negative independent factor in patients with stage IV colorectal cancer undergoing oxaliplatin-based chemotherapy. Anticancer Res. 2013;33(11):5051–5.PubMedGoogle Scholar
  14. 14.
    Lin M, Huang J, Zhu J, Shen H. Elevated pre-treatment levels of high sensitivity C-reactive protein as a potential prognosticator in patients with colorectal cancer. Exp Ther Med. 2013;6(6):1369–74.CrossRefGoogle Scholar
  15. 15.
    Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers. J Gastrointest Surg. 2009;13(11):2011–8 (discussion 2018–9).CrossRefGoogle Scholar
  16. 16.
    Toiyama Y, Inoue Y, Saigusa S, et al. C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery. Anticancer Res. 2013;33(11):5065–74.PubMedGoogle Scholar
  17. 17.
    Toiyama Y, Fujikawa H, Koike Y, et al. Evaluation of preoperative C-reactive protein aids in predicting poor survival in patients with curative colorectal cancer with poor lymph node assessment. Oncol Lett. 2013;5(6):1881–8.CrossRefGoogle Scholar
  18. 18.
    Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680–6.CrossRefGoogle Scholar
  19. 19.
    Min BS, Choi YJ, Pyo HR, et al. Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer. Arch Surg. 2008;143(11):1091–7 (discussion 1097).CrossRefGoogle Scholar
  20. 20.
    Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333(10):609–14.CrossRefGoogle Scholar
  21. 21.
    Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer. 2003;3:28.CrossRefGoogle Scholar
  22. 22.
    Naito Y, Saito K, Shiiba K, et al. CD8 + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58(16):3491–4.PubMedGoogle Scholar
  23. 23.
    Arenberg DA, Keane MP, DiGiovine B, et al. Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother. 2000;49(2):63–70.CrossRefGoogle Scholar
  24. 24.
    Redmond HP. Systemic inflammatory response predicts survival following curative resection of colorectal cancer (Br J Surg 2003;90:215–9). Br J Surg. 2003;90(7):889 (author reply 889).CrossRefGoogle Scholar
  25. 25.
    Shiu YC, Lin JK, Huang CJ, et al. Is C-reactive protein a prognostic factor of colorectal cancer? Dis Colon Rectum. 2008;51(4):443–9.CrossRefGoogle Scholar
  26. 26.
    Cengiz M, Akbulut S, Atahan IL, Grigsby PW. Acute phase response during radiotherapy. Int J Radiat Oncol Biol Phys. 2001;49(4):1093–6.CrossRefGoogle Scholar
  27. 27.
    Barcellos-Hoff MH. Integrative radiation carcinogenesis: interactions between cell and tissue responses to DNA damage. Semin Cancer Biol. 2005;15(2):138–48.CrossRefGoogle Scholar
  28. 28.
    Timaner M, Bril R, Kaidar-Person O, et al. Dequalinium blocks macrophage-induced metastasis following local radiation. Oncotarget. 2015;6(29):27537–54.CrossRefGoogle Scholar
  29. 29.
    Ruegg C, Monnier Y, Kuonen F, Imaizumi N. Radiation-induced modifications of the tumor microenvironment promote metastasis. Bull Cancer. 2011;98(6):47–57.PubMedGoogle Scholar
  30. 30.
    Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409–25.CrossRefGoogle Scholar
  31. 31.
    Dreyer SB, Powell AG, McSorley ST, et al. The pretreatment systemic inflammatory response is an important determinant of poor pathologic response for patients undergoing neoadjuvant therapy for rectal cancer. Ann Surg Oncol. 2017;24(5):1295–303.CrossRefGoogle Scholar
  32. 32.
    Klautke G, Foitzik T, Ludwig K, Klar EJM, Fietkau R. Intensified neoadjuvant chemoradiotherapy (CRT) with capecitabine and irinotecan in patients with locally advanced rectal cancer (LARC): A phase I/II study. J Clin Oncol. 2004;22(14_Suppl):3693-3.CrossRefGoogle Scholar
  33. 33.
    Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638–44.CrossRefGoogle Scholar
  34. 34.
    Rödel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of Surgery, CHA Bundang Medical CenterCHA UniversitySeongnamKorea
  2. 2.Department of SurgeryYonsei University College of Medicine, Yonsei University Health SystemSeoulKorea

Personalised recommendations